Drug intelligence / Profile preview

abediterol

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Inhalation

Overview

Abediterol is a long-acting beta-2 adrenergic receptor agonist (LABA) developed for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It acts by selectively stimulating beta-2 adrenergic receptor in airway smooth muscle, leading to bronchodilation and improved airflow. Abediterol is designed for once-daily dosing due to its prolonged duration of action. The drug was developed by Almirall.

Other names: abediterol

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on abediterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abediterol.

Explore the full profile